At Lys Medical, our mission is clear: to make pulmonary diagnostics faster, more accurate, and accessible worldwide.

Lung cancer remains the leading cause of cancer death globally, largely due to late and uncertain diagnosis. At the heart of Lys Medical’s innovation is Iriscope designed to provide and guarantee direct visualisation of previously unreachable areas of the lung. By enabling real-time, high-yield biopsies under visual control, Iriscope tackles one of the most persistent challenges in pulmonology: low diagnostic yield in peripheral lesions.

Clinical studies have demonstrated Iriscope’s impact:

• Up to 93% positive predictive value for malignancy in visual diagnosis.
• Proven ability to visualise ground-glass opacities and guide decision-making, even when biopsies are inconclusive.

This breakthrough reduces inconclusive diagnoses, avoids unnecessary surgeries, and shortens patient pathways—ultimately improving outcomes and reducing costs.

Beyond technology, Lys Medical has built unique expertise in the peripheral lung, opening new possibilities for pulmonologists and their patients. Our commitment is to empower clinicians with tools that elevate the standard of care, integrate seamlessly into existing workflows, and support training and adoption through dedicated programmes.

Lys Medical is shaping a new paradigm in lung cancer diagnosis.